Joel Wayment, Cardinal Health 3PL Services

Joel Wayment discusses how the cold chain can be more sustainable.

Joel Wayment discusses the implications of the growing cell and gene therapy market on pharma supply chains.

As more of these novel—and costly—cell therapies gain approval, revamped strategies around scaling, coordination and workflow are critical to their launch